Literature DB >> 21940415

JC virus granule cell neuronopathy is associated with VP1 C terminus mutants.

Xin Dang1,2, Jose E Vidal3, Augusto C Penalva de Oliveira3, David M Simpson4, Susan Morgello5, Jonathan H Hecht6, Long H Ngo7, Igor J Koralnik1,2.   

Abstract

The polyomavirus JC (JCV) infects glial cells and causes progressive multifocal leukoencephalopathy (PML). We described a novel JCV-variant with a 10 bp deletion in the C terminus of the VP1 capsid protein, JCV(GCN1). This mutant was associated with lytic infection of cerebellar granule cell neurons and cerebellar atrophy in an human immunodeficiency virus/PML patient. This condition, also observed independently from PML, was named JCV granule cell neuronopathy (JCV GCN). We characterized JCV mutations in cerebrospinal fluid (CSF) of four other JCV GCN patients, and reviewed the literature on 10 reported cases. The strain from one patient harboured the identical GCN1-deletion, while the other patients had novel mutations in the same area, named JCV(GCN2-4), causing variable changes in VP1 structure. One patient also had wild-type JCV in the CSF. To study the mechanisms leading to JCV GCN, we compared viral replication kinetics from JCV(GCN1) with the prototype JCV(Mad1), the PML isolate JCV(HWM) and the prototype JCV(Mad1D) engineered with the GCN1-deletion. While all strains replicated at low levels in the medulloblastoma cell line DAOY from a cerebellar neuronal tumour, JCV(Mad1) replicated better in astroglial SVG cells than JCV(Mad1D) or JCV(GCN1) and all strains replicated at higher levels in COS-7 kidney cells, suggesting that the GCN1-deletion confers a disadvantage for viral growth in central nervous system white matter. The GCN1-deletion remained stable after 100 days in culture and VP1 protein was produced in all cell lines, indicating that JCV(GCN1) is replication-competent in vitro. These data highlight an important and previously overlooked aspect of JCV-pathogenesis. Detection of GCN-type JCV strains in CSF may help clinicians diagnose JCV GCN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940415      PMCID: PMC3352331          DOI: 10.1099/vir.0.037440-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  31 in total

Review 1.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

2.  JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy.

Authors:  Igor J Koralnik; Christian Wüthrich; Xin Dang; Matthew Rottnek; Alejandra Gurtman; David Simpson; Susan Morgello
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

3.  JC viral infection-related cerebellar degeneration as the first manifestation of AIDS.

Authors:  Hae-Won Shin; Suk Y Kang; Young H Sohn
Journal:  Eur Neurol       Date:  2008-01-29       Impact factor: 1.710

Review 4.  Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.

Authors:  Benjamin D Korman; Kenneth L Tyler; Neil J Korman
Journal:  Arch Dermatol       Date:  2009-08

5.  Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity.

Authors:  Leonid Gorelik; Carl Reid; Manuela Testa; Margot Brickelmaier; Simona Bossolasco; Annamaria Pazzi; Arabella Bestetti; Paul Carmillo; Ewa Wilson; Michele McAuliffe; Christopher Tonkin; John P Carulli; Alexey Lugovskoy; Adriano Lazzarin; Shamil Sunyaev; Kenneth Simon; Paola Cinque
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

6.  JC virus granule cell neuronopathy in a child with CD40 ligand deficiency.

Authors:  Jonathan H Hecht; Orit A Glenn; Diane W Wara; Yvonne W Wu
Journal:  Pediatr Neurol       Date:  2007-03       Impact factor: 3.372

7.  Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif.

Authors:  Ursula Neu; Melissa S Maginnis; Angelina S Palma; Luisa J Ströh; Christian D S Nelson; Ten Feizi; Walter J Atwood; Thilo Stehle
Journal:  Cell Host Microbe       Date:  2010-10-21       Impact factor: 21.023

8.  Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

Authors:  Wendy A Knowles; Pam Pipkin; Nick Andrews; Andrew Vyse; Philip Minor; David W G Brown; Elizabeth Miller
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

9.  Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual.

Authors:  R A Du Pasquier; S Corey; D H Margolin; K Williams; L-A Pfister; U De Girolami; J J Mac Key; C Wüthrich; J T Joseph; I J Koralnik
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

10.  Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects.

Authors:  R B Markowitz; H C Thompson; J F Mueller; J A Cohen; W S Dynan
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

View more
  32 in total

1.  A comprehensive proteomics analysis of JC virus Agnoprotein-interacting proteins: Agnoprotein primarily targets the host proteins with coiled-coil motifs.

Authors:  A Sami Saribas; Prasun K Datta; Mahmut Safak
Journal:  Virology       Date:  2019-10-20       Impact factor: 3.616

Review 2.  Expression of novel proteins by polyomaviruses and recent advances in the structural and functional features of agnoprotein of JC virus, BK virus, and simian virus 40.

Authors:  A Sami Saribas; Pascale Coric; Serge Bouaziz; Mahmut Safak
Journal:  J Cell Physiol       Date:  2018-11-02       Impact factor: 6.384

3.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

4.  The human fetal glial cell line SVG p12 contains infectious BK polyomavirus.

Authors:  Stian Henriksen; Garth D Tylden; Alexis Dumoulin; Biswa Nath Sharma; Hans H Hirsch; Christine Hanssen Rinaldo
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 5.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

Review 6.  Immunology of progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Ilijas Jelcic; Wolfgang Faigle; Mireia Sospedra; Roland Martin
Journal:  J Neurovirol       Date:  2015-03-05       Impact factor: 2.643

7.  Frequent infection of neurons by SV40 virus in SIV-infected macaque monkeys with progressive multifocal leukoencephalopathy and meningoencephalitis.

Authors:  Saravanan Kaliyaperumal; Xin Dang; Christian Wuethrich; Heather L Knight; Christine Pearson; John MacKey; Keith G Mansfield; Igor J Koralnik; Susan V Westmoreland
Journal:  Am J Pathol       Date:  2013-10-01       Impact factor: 4.307

8.  A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient.

Authors:  Seweryn Bialasiewicz; Gareth Hart; Kimberly Oliver; Shruti P Agnihotri; Igor J Koralnik; Raphael Viscidi; Michael D Nissen; Theo P Sloots; Michael T Burke; Nicole M Isbel; John Burke
Journal:  Transplantation       Date:  2017-06       Impact factor: 4.939

9.  JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Authors:  Shruti P Agnihotri; Xin Dang; Jonathan L Carter; Terry D Fife; Evelyn Bord; Stephanie Batson; Igor J Koralnik
Journal:  Neurology       Date:  2014-07-18       Impact factor: 9.910

10.  JC polyomavirus mutants escape antibody-mediated neutralization.

Authors:  Upasana Ray; Paola Cinque; Simonetta Gerevini; Valeria Longo; Adriano Lazzarin; Sven Schippling; Roland Martin; Christopher B Buck; Diana V Pastrana
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.